{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-23-047156","form_type":"8-K","ticker":"ERNA","cik":"0000748592","company_name":"Ernexa Therapeutics Inc.","filed_at":"2023-10-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:31.940662+00:00","generated_at":"2026-06-10T04:21:45.114296+00:00","sec_items":["3.01","5.02","8.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Eterna receives Nasdaq delisting notice for audit committee non-compliance; director Fiore resigns","bullets":["Nasdaq notified Eterna on Oct 3, 2023 that audit committee no longer meets minimum three-member/independence requirement after Binder and Wagner resignations.","Cure period: until earlier of next annual meeting or Aug 9, 2024; if meeting before Feb 5, 2024, compliance due by Feb 5, 2024.","Director Gregory Fiore resigned Oct 4, 2023; not due to any disagreement with the company.","Nasdaq closed prior deficiency on independent director/audit/comp committee rules following appointment of Dorothy Clarke on Aug 31 and Sep 26, 2023.","Company evaluating director candidates to regain compliance; listing continues under symbol ERNA on Nasdaq."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-23-047156","json":"https://secwatch.observer/filing/0001140361-23-047156.json","markdown":"https://secwatch.observer/filing/0001140361-23-047156.md","text":"https://secwatch.observer/filing/0001140361-23-047156.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/748592/000114036123047156/0001140361-23-047156-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/748592/000114036123047156/ef20011972_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T04:21:45.114296+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7ff09ae0032a75e6a174a94bc1d810e8b07005a7","claim":"Ernexa Therapeutics Inc. received a nasdaq deficiency notice notice regarding audit committee (rules 5605, 5605(c)(4)).","evidence_excerpt":"October 3, 2023, Eterna Therapeutics Inc. (the “Company”) received a notice (the “Notice”) from the Listing Qualifications Staff (“Staff”) of The Nasdaq Stock Market LLC (the “Nasdaq”) stating that, as a result of the previously disclosed resignations of Mr. Brant C. Binder and Dr. Richard W. Wagner from the Company’s board of directors and audit committee, the Company is no longer in compliance with Nasdaq Listing Rule 5605, which, in relevant part, requires the audit committee to consist of at least three members, each of whom must be an independent director under the Nasdaq Listing Rules","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/748592/000114036123047156/0001140361-23-047156-index.htm","confidence":0.95,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"deficiency notice"},{"label":"Deficiency","value":"audit committee"},{"label":"Rules","value":"5605, 5605(c)(4)"}],"fact_type":"exchange_compliance_notice"},{"claim_id":"9f087baeb0","claim":"Gregory Fiore resigned as Director at Ernexa Therapeutics Inc..","evidence_excerpt":"O n October 4, 2023 Gregory Fiore resigned from the Company’s board of directors.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/748592/000114036123047156/0001140361-23-047156-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}